- Advanced measurable or non-measurable solid tumors
- Adequate bone marrow function
- Adequate liver function
- Adequate renal function
- Be able and willing to comply with the study scheduled visits, treatment plans,
laboratory tests and other procedures
- Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of
first dose of study medication
- Active bleeding disorder, including gastrointestinal bleeding, as evidenced by
hematemesis, hemoptysis or melena in the past 6 months
- Any of the following within the 12 months prior to starting study treatment:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, congestive heart failure, cerebrovascular accident including transient ischemic
attack, or pulmonary embolus; or any other active thromboembolic event
- QTc prolongation defined as QTc >450 msec
- Patients with known brain metastasis
- Patients with peritoneal carcinosis at risk of bleeding
- Major surgical procedure within 4 weeks of treatment
- Pregnancy or breastfeeding